Loading stock data…
Iovance Biotherapeutics (IOVA)
$4.21-0.04 (-0.94%)
After Hours$4.22+0.01 (+0.24%)· Last close Jun 29
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Iovance Biotherapeutics, Inc. in the Healthcare sector is trading at $4.21 with a market capitalization of $1.8B. Wall Street consensus targets $8.80 (10 analysts), implying a +109.0% move over the next 12 months. The stock is currently 25% below its 52-week high of $5.63, remaining 38.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +109.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.43M↓ | $86.77M↑ | $67.45M↑ | $59.95M↑ | $49.32M |
| Gross Profit | $28.93M↓ | $43.66M↑ | $28.98M↑ | $3.29M↓ | $6.61M |
| Operating Income | -$81.04M↓ | -$73.46M↑ | -$89.76M↑ | -$113.77M↑ | -$121.22M |
| Net Income | -$79.05M↓ | -$71.90M↑ | -$91.25M↑ | -$111.66M↑ | -$116.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.03%
Volume
Today's trading volume
10.61M
Recent News
Iovance (IOVA) Surges 9.4% on Regulatory Nod
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Resilient Stocks Beating Market Slump. Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into […]
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.
H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks That Could Skyrocket in 2026. On June 4, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9. The analyst noted two key positive developments for AMTAGVI, which is Iovance’s lead therapy. Firstly, AMTAGVI […]
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated following the Australian approval of Amtagvi. The stock has returned to its pre-approval levels. On June 4, TheFly reported that Iovance […]
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001
While Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has gained 54.95% year-to-date, analysts continue to see 112.80% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Two meaningful pipeline and regulatory developments arrived within days of each other, adding fresh momentum to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s expanding TIL therapy platform. […]